+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07826689

Randomized Study of Oral PRO-1562 for Safety and Remyelination in Healthy Adults and Patients With Relapsing Multiple Sclerosis and Chronic Optic Neuropathy

Led by Progentos Therapeutics · Updated on 2026-09-29

160

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying PRO-1562, an oral drug designed to promote remyelination in the central nervous system, in both healthy adults and adults with relapsing multiple sclerosis RMS who have chronic optic neuropathy. The study aims to evaluate the safety, absorption, and clinical benefits of PRO-1562, including effects on vision, nerve signal speed, cognitive function, and motor skills. This trial is conducted in two phases Phase 1 focuses on healthy adults, while Phase 2a involves RMS patients with long-term vision problems. Phase 1 is a randomized, double-blind, placebo-controlled trial testing single ascending oral doses of PRO-1562 to assess safety and how much drug is absorbed, including lumbar punctures to measure drug crossing the blood-brain barrier. Phase 2a is a 6-month, randomized, double-blind, placebo-controlled trial where adult patients with RMS and chronic optic neuropathy receive once-monthly oral doses of PRO-1562 or placebo alongside their stable MS therapy. After completing 6 months, participants may continue their assigned treatment until the last patient finishes the treatment period. Participants will attend scheduled clinic visits for dosing and assessments, including tests of visual acuity, optic nerve conduction speed, and clinical evaluations of cognition and motor function. Safety is monitored by tracking treatment-emergent adverse events. Blood levels of the drug and brain myelin content are also measured. The total participation duration varies by phase, with Phase 1 lasting until 7 days after dosing, and Phase 2a lasting 6 months of treatment with possible extension until study completion.

CONDITIONS

Brief Title

A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis

Research Team

C

Chief Medical Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here